LH Stock News 99.58 05/14/2014 19:40:44 Laboratory Corporation

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Laboratory Corporation of America Holdings (LH) 99.58 $LH

Health Care Sector Stocks Review -- Research on Stryker, Hansen Medical, Quest Diagnostics, and Laboratory Corporation of America Holdings
PR Newswire - Wed May 14, 9:54AM CDT
On Tuesday, May 13, 2014, the NASDAQ Composite ended at 4,130.17, down 0.33%, the Dow Jones Industrial Average finished the day 0.12% higher at 16,715.44, and the S&P 500 closed at 1,897.45, up 0.04%. The gains were broad based as six out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 676.34, up 0.16%, and the index has advanced 4.90% in the last one month. Investor-Edge has initiated coverage on the following equities: Stryker Corporation (NYSE: SYK), Hansen Medical Inc. (NASDAQ: DGX), Quest Diagnostics Inc. (NYSE: DGX) and Laboratory Corporation of America Holdings (NYSE: LH). Free technical research on SYK, DGX, DGX and LH can be downloaded upon signing up at:

Laboratory Corp of America Holdings Earnings In Retrospect: Up 1.0% in the Last 14 Days (LH)
Comtex SmarTrend(R) - Mon May 12, 7:10AM CDT
When Laboratory Corp of America Holdings (NYSE:LH) reported earnings 14 days ago on April 28th, 2014, analysts, on average, expected the company to report earnings of $1.58 on sales of $1.4 billion. The company actually reported EPS of $1.51 on sales of $1.4 billion, missing EPS estimates by $0.07 and missing revenue estimates by $13.9 million. Shares of Laboratory Corp of America Holdings have climbed from $99.19 to $100.18, representing a gain of 1.0% since the company reported earnings 14 days ago.

Watch for Laboratory Corp of America Holdings to Potentially Pullback After Gaining 1.23% Yesterday
Comtex SmarTrend(R) - Fri May 09, 4:50PM CDT
Laboratory Corp of America Holdings (NYSE:LH) traded in a range yesterday that spanned from a low of $98.72 to a high of $100.49. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $99.95 on volume of 869,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Laboratory Corp of America Holdings Rises 1.23% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Fri May 09, 4:49PM CDT
Laboratory Corp of America Holdings (NYSE:LH) traded in a range yesterday that spanned from a low of $98.72 to a high of $100.49. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $99.95 on volume of 869,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

LabCorp is Scheduled to Present at the Bank of America Merrill Lynch 2014 Health Care Conference
Business Wire - Thu May 08, 7:45AM CDT
Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) today announced that David P. King, Chairman and Chief Executive Officer, is scheduled to speak at the Bank of America Merrill Lynch 2014 Health Care Conference in Las Vegas, NV. LabCorp's presentation is planned for Thursday, May 15, 2014 at 9:20 a.m. (PT).

Earnings Results, Esteemed Recognitions, and Conference Call Schedules - Analyst Notes on Covance, Alere, LabCorp, Charles River and WuXi PharmaTech
PR Newswire - Thu May 08, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Covance Inc. (NYSE: CVD), Alere Inc. (NYSE: ALR), Laboratory Corp. of America Holdings (NYSE: LH), Charles River Laboratories International, Inc. (NYSE: CRL) and WuXi PharmaTech (Cayman) Inc. (NYSE: WX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2179-100free.

Dr. Paul Billings Joins Omicia as Chief Medical Officer
Business Wire - Wed May 07, 10:00AM CDT
Omicia, Inc., the leading genome interpretation company, today announced the appointment of Paul Billings, MD, PhD, FACP, FACMG as Chief Medical Officer (CMO) and will serve on Omicia's Scientific Advisory Board. Dr. Billings joins Omicia as genomics expands from the research lab to become a valuable clinical diagnostic tool. He joins Omicia's leadership as it drives forward the company's vision of individualized medicine enabled by robust genomic interpretation.

Biotech of the Week: Opko Health Inc.
Brian Orelli, The Motley Fool - Motley Fool - Mon May 05, 5:21PM CDT
Opko Health is the biotech of the week for the Fool's biotech-focused show, Biotech Banter . Of course, "biotech" is a bit of a stretch with Opko, because it's working on both diagnostics and therapeutics. On the diagnostics side, Opko Health is...

LabCorp to Webcast Its Annual Meeting of Stockholders
Business Wire - Mon May 05, 4:05PM CDT
Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) today announced that its Annual Meeting of Stockholders will be webcast live beginning May 14, 2014 at 9:00 a.m. Eastern Daylight Time via the Company website at www.labcorp.com. An archived replay of the audio webcast will be available through June 13, 2014.

Insider Trading Alert - APOL, WABC And LH Traded By Insiders
at The Street - Mon May 05, 11:03AM CDT
Stocks with insider trader activity include APOL, WABC and LH

A Healthcare Revolution Could Be Brewing At Your Local Drugstore
Keith Speights, The Motley Fool - Motley Fool - Sun May 04, 12:00PM CDT
Revolution is an overused word. But in this case, it's entirely appropriate. Although you might not be familiar with Theranos yet, you likely will hear plenty about the company over the next few years. Theranos has developed a revolutionary new...

Esteemed Recognitions, Upcoming Conferences, and Solid Quarterly Results - Analyst Notes on Medtronic, Baxter, LabCorp, Jazz Pharmaceuticals and ResMed
PR Newswire - Fri May 02, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Medtronic, Inc. (NYSE: MDT), Baxter International Inc. (NYSE: BAX), Laboratory Corp. of America Holdings (NYSE: LH), Jazz Pharmaceuticals plc (NASDAQ: JAZZ) and ResMed Inc. (NYSE: RMD). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1943-100free.

Global Flonal Endocrine Testing Market Opportunities 2013-2019 - Analysis of the $1.53 Billion Industry
M2 - Fri May 02, 4:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gjmjnk/endocrine_testing) has announced the addition of the "Global Flonal Endocrine Testing Market Opportunities 2013-2019 - Analysis of the $1.53 Billion Industry" report to their offering. The global market for endocrine testing market was valued at USD 1,537.5 million in 2012 growing at a CAGR of 4.3% from 2013 to 2019. Endocrine tests are crucial for monitoring normal functioning of endocrine system since any deviation (hypersecretion or hyposecretion) from the normal levels of hormones results in development of various endocrine disorders such as diabetes, thyroid, cancer and infertility. These tests enable both qualitative and quantitative determination of the hormone levels and can be performed either in hospitals, commercial laboratories (thyroid hormone tests, progesterone tests) or even at home (pregnancy test kit, blood sugar test strips). Endocrine testing market is witnessing increasing growth and adoption majorly due to constant rise in several disorders such as diabetes, thyroid and reproductive system disorders.These disorders indicate the abnormal level of endocrine hormones in the body thereby creating a need and demand for effective endocrine testing kits. In addition, continuous evolution of diagnostic platforms followed by increasing healthcare awareness would further augment the growth and development of endocrine testing platforms. Endocrine testing market can be analyzed by the type of tests involved, diagnostic platforms and end users. The various hormone tests refer to estradiol, Follicle Stimulating Hormone (FSH), Human Chorionic Gonadotropin (hCG), Luteinizing Hormone (LH), Dehydroepiandrosterone sulfate (DHEAS), Progesterone, Testosterone, Thyroid Stimulating Hormone (TSH), Prolactin, Cortisol, Insulin tests and others. Thyroid stimulating hormone test market was estimated to be the largest market segment in 2012 growing at a CAGR of 5.4% during the forecast period. This is attributed to high prevalence of thyroid disorders among geriatric population and also is more common in females than males with a female to male ratio of 10:1. Also, as per the research findings published in Elsevier, Inc., among the population aged above 65, 1.7% have hypothyroidism and 13.7% of aging population have subclinical hypothyroidism. Insulin test is expected to be the fastest growing segment during the forecast period from 2013 to 2019. The major reason being constant rise in diabetic and obese population across the globe. The global endocrine testing market is segmented into the following categories: Tests - Estradiol (E2) Test - Follicle Stimulating Hormone (FSH) Test - Human Chorionic Gonadotropin (hCG) Test - Luteinizing Hormone (LH) Test - Dehydroepiandrosterone sulfate (DHEAS) Test - Progesterone Test - Testosterone Test - Thyroid Stimulating Hormone (TSH) Test - Prolactin Test - Cortisol Test - Insulin Test - Others (Gastrin, Thymosin, Secretin, etc.) Diagnostic Technologies - Tandem Mass spectrometry - Immunoassay (Enzyme immunoassays, Radioimmunoassays (RIA)) Technologies - Monoclonal and Polyclonal Antibody Technologies - Sensor (Electrochemical, Biosensors, etc.) Technologies - Clinical Chemistry Technologies - Others (Liquid Chromatography Mass Spectrometry (LC-MS), High performance Liquid Chromatography (HPLC), etc.) Location - Hospitals - Commercial Laboratories - Ambulatory Care Centers - Home Based Tests - Physician Offices Companies Mentioned - Abbott Laboratories - AB SCIEX LLC - Agilent Technologies - Biomedical Diagnostics - bioMerieux - Bio-Rad Laboratories, Inc. - DiaSorin S.p.A - F. Hoffmann-La Roche Ltd. - Laboratory Corporation of America Holdings (LabCorp) - Ortho Clinical Diagnostics - Quest Diagnostics - Siemens Healthcare - Sysmex Corporation - Thermo Fisher Scientific For more information visit http://www.researchandmarkets.com/research/gj...ne_testing

LabCorp Lags on Earnings & Revs, Ups View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 28, 12:23PM CDT
Laboratory Corp. of America Holdings (LH), popularly known as LabCorp, is expected to release its first-quarter 2014 results before the opening bell on Apr 25.

Laboratory Corp. of America Holdings Ascribes Earnings Miss to Harsh Winter Weather
Anders Bylund, The Motley Fool - Motley Fool - Mon Apr 28, 11:24AM CDT
Image source: LabCorp Laboratory Corp. of America , popularly known as LabCorp, just reported results for the first quarter of fiscal year 2014. The company missed Wall Street estimates on both the top and bottom lines, and points to harsh...

Water-Logged And Getting Wetter Stock Of The Day: Laboratory Corp Of America Hldgs (LH)
at The Street - Mon Apr 28, 8:51AM CDT
Trade-Ideas LLC identified Laboratory Corp of America Hldgs (LH) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate

Laboratory Corporation of America(R) Holdings Announces 2014 First Quarter Results and Updates 2014 Guidance
Business Wire - Mon Apr 28, 6:03AM CDT
--Diluted EPS of $1.31

Quest Diagnostic Misses on Q1 Earnings, Ups Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 1:47PM CDT
Quest Diagnostics (DGX) reported first-quarter 2014 adjusted earnings per share from continuing operations of 84 cents.

Financial Releases Schedules -- Research on Aon PLC, Laboratory Corp. of America Holdings, Lear, and Ford Motor
PR Newswire - Thu Apr 24, 7:00AM CDT
Earningsource.com provides investors with earnings schedule updates throughout the earnings season. With timely information on past earnings performance and earnings projection for their upcoming quarterly release, our aim is to ensure shareholders and traders have an edge on their investment decisions on the following companies: Aon PLC (NYSE: AON), Laboratory Corp of America Holdings (NYSE: LH), Lear Corp. (NYSE: LEA) and Ford Motor Co. (NYSE: F). Full earnings notes on AON, LH, LEA and F can be downloaded upon signing up at:

Will LabCorp (LH) Miss Earnings Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 22, 11:30AM CDT
LabCorp is expected to release its first-quarter 2014 results before the opening bell on Apr 25.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 501

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 130

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 564

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 707

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 445

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 270

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 299

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 112

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 496

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading